The way ahead for HEOR in biopharma should be built on increasing C-suite visibility and understanding of the value contribution that HEOR makes and demonstrating that a failure to invest in HEOR puts companies at a competitive disadvantage, especially in the face of rising regulatory and payer expectations for evidence.
The “holy grail” of ATMP-based treatments is to provide cures for some of the world’s most debilitating disease states, but for this to occur, a unified front is needed to democratize these therapies – collaboration from industry, academia, supply chain and, indeed, clinicians and hospitals is paramount to ensuring safe manufacturing and transit.
Transitioning to PDPM models significantly shifted the healthcare industry. By replacing the RUG system, healthcare providers cut waste and more accurately reflect the care each patient received.
Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more.
Anita Nelsen, Senior Vice President of Clinical Trial Operations at Allucent, shares her insights on how to navigate the drug development landscape.
In the runup to INVEST and the startup pitch contest, we highlight trends in investment and innovation across bipharma, diagnostics, medical devices, health tech: payer/provider, and health tech: consumer/employer. The deadline has been extended until February 28 and finalists will be announced March 31. Apply today!
With five tracks of startups across healthcare and life sciences, INVEST Pitch Perfect, scheduled for May 22-24 at the Ritz Carlton in Chicago, is MedCity's largest startup pitch contest of the year.
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Maina Bhaman, a board member of CinCor Pharma reflects on the news from Monday that AstraZeneca is acquiring the Massachusetts startup to bring another option for patients with resistant hypertension.
The Covid-19 pandemic has forced life sciences companies to take a fresh look at how they do business. But as they reinvent their operations, companies often overlook a critical function: Their learning and development programs.
Read about executive hires across healthcare and life sciences.
A former Theranos lab director who testified during Elizabeth Holmes' trial said he's had trouble sleeping because of regrets about the trial and showed up at her door "disheveled" and wanting to talk.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S., the European Union and other countries amid ongoing efforts to encourage patients who want to share their data.
Emergn Principal Consultant Mario Moreira shared insights on how pharma companies can use the principles of Value, Flow and Quality to shorten drug development timelines and deliver better patient outcomes through improved ways of working.
The French delegation at BIO on June 13-16 has a compelling story to tell about biopharma and medtech growth and investment in France and the U.S. Here's a preview of some of the companies that will be at the convention, events they will host and why you should check them out.
Founded in 2021, Gandeeva is developing precision imaging solutions with the integration of cryo-electron microscopy (cryo-EM) and artificial intelligence. Its technology can be applied to advance drug discovery and by lowering risks of late-stage clinical failures.
MedCity INVEST PharmaTech, a virtual conference scheduled for July 26, will bring together technology disruptors, Big Pharma and biotech leaders, investors and entrepreneurs to discuss how to adopt digital strategies to transform every aspect of the pharma industry.